Skip to main content

auryxia

Generic: ferric citrate

auryxia: sourced relationships with 1 company · 1 FDA decision.

auryxia evidence translation

What we can confirm

What it means

Source-backed records connect auryxia to KERYX; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could auryxia → KERYX affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Treatment of iron deficiency anemia in adults with CKD, not on dialysis

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
KERYX BIOPHARMACEUTICALS INC (KERYX)
developer · Reported 2018-02-21 · Current development: unknownSource
Treatment of iron deficiency anemia in adults with CKD, not …
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE Ferric citrate tablets are a phosphate binder indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis. ( 1 ) Ferric citrate tablets are an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis. ( 1 ) 1.1 Hyperphosphatemia in Chronic Kidney Disease on Dialysis Ferric citrate tablets are indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis. 1.2 Iron Deficiency Anemia in Chronic Kidney Disease Not on Dialysis Ferric citrate tablets are indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis.(KERYX)FDA ↗
NDA205874Type 5 - New Formulation or New ManufacturerStandardOralTablet

Frequently asked questions

Which companies have sourced relationships with auryxia?

auryxia has dated SEC/FDA relationship records for KERYX BIOPHARMACEUTICALS INC.

What is auryxia's latest FDA decision?

The most recent tracked FDA decision for auryxia is Approval for 1 INDICATIONS AND USAGE Ferric citrate tablets are a phosphate binder indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis. ( 1 ) Ferric citrate tablets are an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis. ( 1 ) 1.1 Hyperphosphatemia in Chronic Kidney Disease on Dialysis Ferric citrate tablets are indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis. 1.2 Iron Deficiency Anemia in Chronic Kidney Disease Not on Dialysis Ferric citrate tablets are indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis., dated September 5, 2014.